Core Points - The Gross Law Firm has issued a notice to shareholders of CarMax, Inc. regarding a class action lawsuit for alleged misleading statements made by the company during the class period from June 20, 2025, to September 24, 2025 [1] - The allegations include that CarMax's growth prospects were overstated and that earlier growth was a temporary effect due to customer speculation about tariffs, leading to materially false and misleading statements about the company's business and operations [1] Summary by Sections Class Action Details - Shareholders who purchased shares of CarMax during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1] - The deadline for shareholders to register for the class action is January 2, 2026, and there is no cost or obligation to participate [2] Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3]

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects [1]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted [1]. - There was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [1]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [1]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [1]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-su ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which were not authorized by the FDA and posed health risks to users [1]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring devices, which rendered them less reliable than previous versions [1]. - It is alleged that the enhancements to the G7's reliability, accuracy, and functionality were overstated, and the company downplayed the severity of the issues related to the devices [1]. - The complaint suggests that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Freeport-McMoRan Inc. (NYSE: FCX) for allegedly issuing false and misleading statements regarding safety practices at the Grasberg Block Cave mine in Indonesia, which may have led to increased risks for workers and potential regulatory and reputational consequences [1]. Group 1: Allegations and Class Period - The class period for the lawsuit is from February 15, 2022, to September 24, 2025 [1]. - Allegations include failure to ensure adequate safety measures at the Grasberg Block Cave mine, which posed a heightened risk of worker fatalities [1]. - The complaint asserts that the lack of proper safety precautions led to undisclosed risks related to regulatory, litigation, and reputational issues [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased FCX shares during the specified class period are encouraged to register for the class action by January 12, 2026 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case does not incur any costs or obligations for shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit, fraud, and illegal business practices [3]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [3]. - The firm seeks recovery for investors affected by misleading statements or omissions that artificially inflated stock prices [3].

Core Viewpoint - ICU Medical, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to engaging with investors and stakeholders in the healthcare sector [1]. Group 1: Event Participation - Company management will take part in a fireside chat on December 4, 2025, at 10:00 a.m. PT (1:00 p.m. ET) [1]. - In addition to the fireside chat, management will engage in one-on-one meetings on the same day [1]. Group 2: Webcast Information - The fireside chat will be available for live streaming on the company's website, with a replay option also provided [2]. Group 3: Company Overview - ICU Medical is a global leader in infusion systems and critical care products, serving hospital, alternate site, and home care settings [3]. - The company is headquartered in San Clemente, California, and focuses on quality, innovation, and value for clinical customers worldwide [3].

Market Overview - The current market is experiencing sideways movement, with optimism and caution balancing each other, leading to elevated valuations near record highs [1] - Mixed economic data and uncertain Federal Reserve timing are preventing investors from adopting a fully bullish stance [1] - Earnings reports have been solid but not catalytic, resulting in a stable yet selective market with modest and uneven gains [1] Broker Recommendations - Following brokers' recommendations can help investors identify potential winning stocks, such as Insulet Corporation (PODD), Sandisk Corporation (SNDK), and O-I Glass, Inc. (OI) [2] - Brokers develop informed perspectives through direct engagement with management, detailed analysis of public disclosures, and participation in earnings calls, providing valuable context for stock performance [3] Stock Performance and Projections - Insulet (PODD) is expected to see a 50.9% year-over-year increase in earnings for 2025 and has experienced a 4% upward revision in broker ratings over the past four weeks [8][9] - Sandisk (SNDK) is projected to have a 308% surge in fiscal 2026 earnings year-over-year and has seen a 5.6% increase in broker ratings [10] - O-I Glass (OI) anticipates a 96.3% year-over-year jump in 2025 earnings, with a 10% rise in broker ratings recently [11] Stock Selection Strategy - A screening strategy is proposed to identify stocks with broker rating upgrades of 1% or more over the past four weeks, priced above $5, and with an average 20-day volume greater than 100,000 [5] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) have a proven record of success, especially when combined with a VGM Score of A or B [6]

Core Insights - Catheter Precision, Inc. has achieved rapid commercial uptake of its LockeT closure device in South Africa, indicating strong market demand for its product [1][2]. Group 1: Product Implementation - The LockeT device was successfully implemented in five hospitals within two months, with three hospitals using it daily and two using it routinely [2]. - All five hospitals have placed reorders for the LockeT device through the local distributor, HLC Medical [2]. Group 2: Market Importance - The swift adoption of LockeT highlights its significance in emerging markets, where cost-effectiveness and improved workflow are critical [3]. - LockeT is designed to enhance patient care by enabling rapid hemostasis, which allows for same-day discharge [3]. Group 3: Product Overview - LockeT is a suture retention device intended for wound closure after percutaneous venous punctures and is classified as a Class 1 device registered with the FDA, also holding CE Mark approval [4]. Group 4: Company Background - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, emphasizing collaboration with physicians to advance its products [5].

Core Insights - Envoy Medical has secured a new U.S. patent for an innovative cochlear implant system that features a removable earplug sensor and an implanted battery, reinforcing its leadership in next-generation cochlear implant technology [1][2][3] Company Developments - The newly granted patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," enhances Envoy Medical's intellectual property portfolio and covers systems that include an implantable subsystem with a stimulator and rechargeable energy storage [2][3] - The patent supports the company's long-term innovation strategy and aims to protect future advancements in implanted technologies, not just current devices [3] - Envoy Medical is making positive progress in its pivotal Acclaim® Cochlear Implant clinical trial, which has received Breakthrough Device Designation from the FDA in 2019 [3][4][8] Product Information - The Acclaim Cochlear Implant is designed for individuals with severe to profound sensorineural hearing loss and utilizes a sensor that leverages the natural anatomy of the ear instead of a microphone [7][8] - The Esteem® fully implanted active middle ear implant is another innovative product from Envoy Medical, which has been commercially available in the U.S. since 2010 and allows for continuous hearing without external components [5][9]

Abbott Laboratories agrees to buy the cancer screening company in a cash deal. ...